BioSpace News Archive

Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).

Vaxart (NASDAQ: VXRT) today reported additional phase 1 clinical data published on medRixv.org, indicating that its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against SARS-CoV-2 the virus that causes COVID-19, and all tested coronaviruses.

ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced today the launch of their Premier Early Access Program and recruitment of participation from key biopharmaceutical industry partners and leading academic centers.

PLT Health Solutions, Inc announced the publication of a clinical study on its Boswellia serrata -based AprèsFlex ® 5-Day Joint Support ingredient that provides further evidence of its ability to support joint health and function with statistically significant improvements in pain scores and biomarkers starting at only five days from initial consumption.

G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET.

Cosmos Holdings, Inc. announced that it has entered into a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

Halberd Corporation (OTC Pink: HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary.

Olympus Corporation of the Americas, a leading medical technology company, scored 90 out of 100 in its inaugural inclusion on Disability:IN’s 2022 Disability Equality Index, a comprehensive tool that helps companies work toward disability inclusion.

Constant Therapy Health, a brain health digital therapeutics company, announced today the publication of a dosage study in the Journal of Medical Internet Research entitled, “Dosage Frequency Effects on Treatment Outcomes Following Self-managed Digital Therapy: Retrospective Cohort Study”.

As the Omicron variant of SARS-CoV-2 spread rapidly around the globe earlier this year, researchers at Gladstone Institutes, UC Berkeley, and the Innovative Genomics Institute used virus-like particles to identify which parts of the virus are responsible for its increased infectivity and spread.